We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA investigators observed employees at Piramal Critical Care’s Bethleham, Pa., plant using potable water in the manufacture of finished drugs, which resulted in a Form 483.